Drug Approval | October 02, 2024
Zydus receives EIR for the transdermal manufacturing facility
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Subscribe To Our Newsletter & Stay Updated
